HRK Supply Nifuroxazide raw Materials powder

CAS:965-52-6

MF:C12H9N3O5

MW:275.22

EINECS:213-522-0

Specification​: 99% min Nifuroxazide Powder

Sample:Nifuroxazide Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:yellow

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Nifuroxazide Powder Usage and Synthesis.

Nifurphenol hydrazide is mainly used to prevent and treat bacillary dysentery and enteritis. Prevention and treatment of intestinal or urinary diseases caused by E. coli, Salmonella, Pasteurella (including Riederia), aerogenes, Proteus, necrobacterium and staphylococcus. It can effectively prevent dysentery, has wide antibacterial spectrum, high antibacterial activity and low antibacterial concentration. No cross-resistance with sulfonamides, quinolones and other antibiotics.

Uses of Nifuroxazide.

Nifuroxazide prevents intestinal or urinary diseases caused by E. coli, Salmonella, Pasteurella (including Riederia), aerogenes, Proteus, necrobacterium and staphylococcus. It can effectively prevent dysentery and promote animal feeding.

In vitro study of Nifuroxazide.

Nifuroxazide is a nitrofuran compound inhibitor that inhibits STAT transcription factor signal transduction. Nifuroxazide inhibits STAT3 constitutive phosphorylation by reducing Jak kinase self-phosphorylation, thereby reducing myeloma cell viability without affecting normal peripheral blood mononuclear cells. Nifuroxazide decreased tyrosine phosphorylation of Jak and TYK2, but had no effect on EGF receptor tyrosine kinase or Src kinase, indicating the relative specificity of Nifuroxazide for Jak2 and TYK2.

Nifuroxazide did not inhibit Akt or MAPK phosphorylation. Nifuroxazide inhibits the constitutive phosphorylation of STAT3 in MM cells by reducing the self-phosphorylation of Jak kinase, and leads to downregulation of the STAT3 target gene Mcl-1. Nifuroxazide caused a decrease in survival activity of primary myeloma cells and myeloma cell lines containing STAT3 activation, but did not affect normal peripheral blood mononuclear cells. While bone marrow stromal cells provide signals for myeloma cells to survive, nifuroxazide blocks this survival advantage. nifuroxazide showed stronger cytotoxicity when bound to the histone deacetylase inhibitor peptide or the MEK inhibitor UO126 compared to the interaction of STAT3 with other cellular pathways.

Product method of Bulk Nifuroxazide Powder.